KODKodiak Sciences Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$216M
- 29% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$267M | −$341M | −$277M | −$187M | −$234M | 25% |
| Net income | −$267M | −$334M | −$260M | −$176M | −$230M | 31% |
| Operating cash flow | −$182M | −$206M | −$154M | −$117M | −$136M | 16% |
| Capex | $17M | $37M | $41M | $375K | $506K | 35% |
| Stock-based comp | $61M | $106M | $89M | $60M | $59M | 2.2% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $157M · 82
- Open-market sells, 12 mo
- $3M · 8
- Net
- $154M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $24M | 391 | — |
| FY2024 | $2M | $11M | 12 | — |
| FY2023 | $3M | −$830K | 4 | — |